Helmut Albrecht to HIV-1
This is a "connection" page, showing publications Helmut Albrecht has written about HIV-1.
Connection Strength
0.735
-
A click chemistry amplified nanopore assay for ultrasensitive quantification of HIV-1 p24 antigen in clinical samples. Nat Commun. 2022 Nov 11; 13(1):6852.
Score: 0.186
-
Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019 06; 6(6):e364-e372.
Score: 0.146
-
Disparities in viral load and CD4 count trends among HIV-infected adults in South Carolina. AIDS Patient Care STDS. 2015 Jan; 29(1):26-32.
Score: 0.108
-
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013 Nov; 13(11):927-35.
Score: 0.099
-
CD127 and CD25 expression defines CD4+ T cell subsets that are differentially depleted during HIV infection. J Immunol. 2008 Apr 15; 180(8):5582-92.
Score: 0.068
-
Loss of CD127 expression defines an expansion of effector CD8+ T cells in HIV-infected individuals. J Immunol. 2005 Mar 01; 174(5):2900-9.
Score: 0.055
-
Cost-Effectiveness Analysis of Early vs Late Diagnosis of HIV-Infected Patients in South Carolina. South Med J. 2018 06; 111(6):355-358.
Score: 0.034
-
Transmitted antiretroviral drug resistance in individuals with newly diagnosed HIV infection: South Carolina 2005-2009. South Med J. 2011 Feb; 104(2):95-101.
Score: 0.021
-
Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS One. 2010 Jun 16; 5(6):e11160.
Score: 0.020